CymitQuimica logo

CAS 1505515-69-4

:

Formule :C29H34FN5O5
InChI :InChI=1S/C23H24FN5O.C6H10O4/c1-15(25)14-30-20-8-6-17(7-9-20)21-13-26-23-11-10-22(28-29(21)23)27-16(2)18-4-3-5-19(24)12-18;7-5(8)3-1-2-4-6(9)10/h3-13,15-16H,14,25H2,1-2H3,(H,27,28);1-4H2,(H,7,8)(H,9,10)/t15-,16-;/m1./s1
Code InChI :DORJQZDOULKINH-QNBGGDODSA-N
SMILES :C[C@H](COC1=CC=C(C=C1)C2=CN=C3N2N=C(C=C3)N[C@H](C)C4=CC(=CC=C4)F)N.C(CCC(=O)O)CC(=O)O
5 produits trouvés.
  • Taletrectinib

    CAS :
    Taletrectinib
    Formule :C29H34FN5O5
    Degré de pureté :99.5%
    Masse moléculaire :551.61

    Ref: 54-BUP03569

    5mg
    225,00€
    10mg
    343,00€
    25mg
    524,00€
    50mg
    759,00€
    100mg
    1.028,00€
    200mg
    1.304,00€
  • Taletrectinib

    CAS :
    3-(4-((R)-2-Aminopropoxy)phenyl)-N-((R)-1-(3-fluorophenyl)ethyl)imidazo[1,2-b]pyridazin-6-amine adipate
    Formule :C29H34FN5O5
    Degré de pureté :99%
    Masse moléculaire :551.61
  • Taletrectinib

    CAS :
    Taletrectinib (AB-106) is a new-generation selective inhibitor of ROS1/NTRK including ROS1,NTRK1,NTRK2 and NTRK3.
    Formule :C29H34FN5O5
    Degré de pureté :99.87% - 99.96%
    Couleur et forme :White Solid
    Masse moléculaire :551.6092
  • Taletrectinib Adipate

    Produit contrôlé
    CAS :
    Formule :C29H34FN5O5
    Couleur et forme :Neat
    Masse moléculaire :551.62

    Ref: TR-T757780

    100mg
    8.040,00€
  • Taletrectinib

    CAS :
    Taletrectinib is a small molecule that inhibits the activity of serine proteases, including caspase-3 and cathepsin B. Taletrectinib binds to the active site of these enzymes, preventing them from cleaving their substrate proteins. It has been shown to have antitumor activity in cell cultures as well as in mice with tumors. This drug has a terminal half-life of about 6 hours in human plasma. The safety profile of taletrectinib is similar to those of other drugs used for cancer treatment. This drug has been tested in phase 1 clinical trials and demonstrated an escalation dose response effect. In addition, it demonstrated a favorable safety profile with limited toxicity profiles. Taletrectinib targets lesions on zymogens that are not accessible by other drugs such as lorlatinib or ibrutinib.br> br> Taletrectinib is also being developed for the treatment of neuroendocrine
    Formule :C29H34FN5O5
    Degré de pureté :Min. 95%
    Masse moléculaire :551.6 g/mol